Tayná Evily de Lima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tayná Evily de Lima has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Isabelle Freire Tabosa Viana
Graduate Programme on Materials Science—PPGMTR, Federal University of Pernambuco—UFPE, Recife 50670-901, Brazil
2 shared publications - Roberto Dias Lins
Affiliations Department of virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil, Fiocruz Genomic Network, Oswaldo Cruz Foundation, Recife, Brazil
2 shared publications - Alberto José da Silva Duarte
Laboratory of Medical Investigation in Dermatology and Immunodeficiencies (LIM-56), Hospital das Clinicas HCFMUSP, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil, usp.br
1 shared publication - Alexandre de Almeida
ILaboratorio de Investigacao Medica em Dermatologia e Imunodeficiencias (LIM 56), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR
1 shared publication - Bruna Tiaki Tiyo
Laboratory of Medical Investigation in Dermatology and Immunodeficiencies (LIM-56) Clinical Hospital HCFMUSP Faculty of Medicine University of Sao Paulo, Sao Paulo, SP, Brazil
1 shared publication - Carlos Alexandre Antunes de Brito
Postgraduate Program in Tropical Medicine, Center of Medical Sciences, Universidade Federal de Pernambuco (UFPE), Federal University of Pernambuco, Recife, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 96 (2) , e20230894
Determination of prognostic markers for COVID-19 disease severity using routine blood tests and machine learning
The need for the identification of risk factors associated to COVID-19 disease severity remains urgent. Patients’ care and resource allocation can be potentially different and are defined based on the current classification of disease severity. This classification is based on the analysis of clinical parameters and routine blood tests, which are not standardized across the globe. Some laboratory test alterations have been associated to COVID-19 severity, although these data are conflicting partly due to the different methodologies used across different studies. This study aimed to construct and validate a disease severity prediction model using machine learning (ML). Seventy-two patients admitted to a Brazilian hospital and diagnosed with COVID-19 through RT-PCR and/or ELISA, and with varying degrees of disease severity, were included in the study. Their electronic medical records and the results from daily blood tests were used to develop a ML model to predict disease severity. Using the above data set, a combination of five laboratorial biomarkers was identified as accurate predictors of COVID-19 severe disease with a ROC-AUC of 0.80 ± 0.13. Those biomarkers included prothrombin activity, ferritin, serum iron, ATTP and monocytes. The application of the devised ML model may help rationalize clinical decision and care.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 96 (2) , e20230894
Open AccessDetermination of prognostic markers for COVID-19 disease severity using routine blood tests and machine learning
The need for the identification of risk factors associated to COVID-19 disease severity remains urgent. Patients’ care and resource allocation can be potentially different and are defined based on the current classification of disease severity. This classification is based on the analysis of clinical parameters and routine blood tests, which are not standardized across the globe. Some laboratory test alterations have been associated to COVID-19 severity, although these data are conflicting partly due to the different methodologies used across different studies. This study aimed to construct and validate a disease severity prediction model using machine learning (ML). Seventy-two patients admitted to a Brazilian hospital and diagnosed with COVID-19 through RT-PCR and/or ELISA, and with varying degrees of disease severity, were included in the study. Their electronic medical records and the results from daily blood tests were used to develop a ML model to predict disease severity. Using the above data set, a combination of five laboratorial biomarkers was identified as accurate predictors of COVID-19 severe disease with a ROC-AUC of 0.80 ± 0.13. Those biomarkers included prothrombin activity, ferritin, serum iron, ATTP and monocytes. The application of the devised ML model may help rationalize clinical decision and care.
- Open Access
SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients
In this preliminary study we investigated cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in blood samples from 14 recovered coronavirus disease 2019 (COVID-19) patients and compared them ...
Open AccessSARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients
In this preliminary study we investigated cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in blood samples from 14 recovered coronavirus disease 2019 (COVID-19) patients and compared them ...